<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="238693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002651</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064184</org_study_id>
    <secondary_id>SWOG-9346</secondary_id>
    <secondary_id>CAN-NCIC-PR8</secondary_id>
    <secondary_id>CALGB-9594</secondary_id>
    <secondary_id>ECOG-S9346</secondary_id>
    <secondary_id>EORTC-30985</secondary_id>
    <secondary_id>CAN-NCIC-JPR8</secondary_id>
    <secondary_id>INT-0162</secondary_id>
    <nct_id>NCT00002651</nct_id>
  </id_info>
  <brief_title>Hormone Therapy in Treating Men With Stage IV Prostate Cancer</brief_title>
  <official_title>Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
      may be effective treatment for prostate cancer. It is not yet known which regimen of hormone
      therapy is most effective for stage IV prostate cancer.

      PURPOSE: This randomized phase III trial is studying two different regimens of hormone
      therapy and comparing how well they work in treating men with stage IV prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the survival of patients with metastatic stage IV prostate cancer responsive to
           combined androgen-deprivation therapy (CAD) treated with intermittent vs continuous
           CAD.

        -  Compare the effects of these treatment regimens on impotence, libido, and
           vitality/fatigue as well as the physical and emotional well-being of these patients.

      Secondary

        -  Compare general symptoms, role functioning, global perception of quality of life, and
           social functioning of patients treated with these regimens.

        -  Assess prostate-specific antigen (PSA) levels after continuous CAD administered before
           randomization and evaluate PSA changes throughout randomized treatment of these
           patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to SWOG
      performance status (0-1 vs 2), severity of disease (minimal vs extensive), and prior
      hormonal therapy (neoadjuvant hormonal therapy vs finasteride vs neither).

        -  Induction therapy: Patients receive combined androgen-deprivation (CAD) therapy
           comprising goserelin subcutaneously once a month and oral bicalutamide once daily for 8
           courses (7 months).

        -  Consolidation therapy: Patients are randomized to 1 of 2 consolidation regimens.

             -  Arm I (continuous CAD therapy): Patients continue CAD therapy as in induction
                therapy. Treatment continues in the absence of disease progression.

             -  Arm II (intermittent CAD therapy): Patients undergo observation in the absence of
                rising prostate-specific antigen (PSA) or clinical symptoms of progressive
                disease. Patients with rising PSA or progressive disease begin CAD therapy as in
                induction therapy. Patients whose PSA normalizes after 8 courses return to
                observation. Patients whose PSA does not normalize after 8 courses continue CAD
                therapy.

      Quality of life is assessed before induction therapy, at 3 months (before consolidation
      therapy), and then at 9 and 15 months.

      Patients are followed every 6-12 months for at least 10 years.

      PROJECTED ACCRUAL: Approximately 1,500 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 1995</start_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-specific symptoms as measured on the four-item Medical Outcomes Study Short Form-36 (SF-36) and Vitality scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical functioning as measured by the SF-36</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotional functioning as measured by the SF-36 Mental Health Inventory</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms as assessed by the Symptom Distress Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role functioning as assessed by the Role Functioning Scale SF-20</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social functioning as assessed by the General Health Survey SF-20</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global quality of life (QOL) and health-related QOL</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity, social support, and demographic variables</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1512</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical observation</intervention_name>
    <description>Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.</description>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

               -  Metastatic stage IV (stage D2)

                    -  Any number of bone metastases by bone scan allowed

                    -  Unequivocal visceral organ metastases (liver, brain, or lung) allowed

               -  No suspected second primary tumors unless metastases are histologically
                  confirmed, including special stains (e.g., prostate specific antigen [PSA] and
                  prostatic alkaline phosphatase [PAP])

          -  For entry into late induction therapy:

               -  No more than 1 month from the beginning of antiandrogen therapy to the beginning
                  of luteinizing hormone-releasing hormone (LHRH) agonist therapy

               -  No more than 6 months since initiation of current combined androgen-deprivation
                  therapy (LHRH agonist and antiandrogen)

               -  The effectiveness of the current depot LHRH agonist would not extend beyond 8
                  months after initiation of combined androgen therapy

          -  PSA at least 5 ng/mL

          -  No acute spinal cord compression

        PATIENT CHARACTERISTICS:

        Age:

          -  Adult

        Performance status:

          -  SWOG 0-2

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Recovered from any major infection

          -  No active medical illness that would preclude study or limit survival

          -  No other malignancy within the past 5 years except:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Adequately treated carcinoma in situ of the bladder

               -  Adequately treated other superficial cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biological response modifier therapy

        Chemotherapy:

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  More than 1 year since any prior neoadjuvant or adjuvant hormonal therapy for a
             duration of no more than 4 months

               -  Single or combination therapy allowed

          -  More than 1 year since prior finasteride for prostate cancer for a duration of no
             more than 9 months (less than 6 months for benign prostatic hypertrophy)

          -  Prior or concurrent megestrol for hot flashes allowed

          -  No other concurrent hormonal therapy

        Radiotherapy:

          -  No concurrent radiotherapy other than palliation of painful bone metastases

        Surgery:

          -  No prior bilateral orchiectomy

          -  Recovered from any prior major surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha Hadi A. Hussain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan J. Donnelly, MD, FRCSC, MSC</last_name>
    <role>Study Chair</role>
    <affiliation>Tom Baker Cancer Centre - Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric J. Small, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Wilding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atif Akdas, MD</last_name>
    <affiliation>Marmara University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Donnelly</last_name>
      <phone>403-259-2676</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute at University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Venner</last_name>
      <phone>780-432-8757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Larry Goldenberg</last_name>
      <phone>604-875-4111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Wilke</last_name>
      <phone>902-473-6022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamer Mahmud</last_name>
      <phone>613-544-2631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Chin</last_name>
      <phone>519-685-8451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libni Eapen</last_name>
      <phone>613-737-7700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Klotz</last_name>
      <phone>416-480-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita Crook</last_name>
      <phone>416-946-4501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Saad</last_name>
      <phone>514-890-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raghu Rajan</last_name>
      <phone>514-934-1934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Lacombe</last_name>
      <phone>418-691-5O50</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS-Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdenour Nabid</last_name>
      <phone>819-346-1110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B. Gardiner</last_name>
      <phone>306-655-2743</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Malta</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM Jr. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct;188(4):1164-9. doi: 10.1016/j.juro.2012.06.046. Epub 2012 Aug 22.</citation>
    <PMID>22921015</PMID>
  </reference>
  <reference>
    <citation>Hussain M, Tangen CM, Higano CS, et al.: Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (pca): better efficacy or stage migration? Data from SWOG: S9346 and 8894. [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-30, 2010.</citation>
  </reference>
  <reference>
    <citation>Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20.</citation>
    <PMID>19380444</PMID>
  </reference>
  <reference>
    <citation>Goldman B, Hussain M, Tangen C, et al.: Prostate-specific antigen progression (PSA-P) as a predictor of overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-165, 2008.</citation>
  </reference>
  <reference>
    <citation>Hussain MH, Goldman B, Tangen CM, et al.: Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. [Abstract] J Clin Oncol 26 (Suppl 15): A-5015, 2008.</citation>
  </reference>
  <results_reference>
    <citation>Hussain M, Tangen CM, Higano CS, et al.: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. [Abstract] J Clin Oncol 30 (Suppl 15): A-4, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Moinpour C, Berry DL, Ely B, et al.: Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)â€”phase III. [Abstract] J Clin Oncol 30 (Suppl 15): A-4571, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162).. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20;24(24):3984-90.</citation>
    <PMID>16921051</PMID>
  </results_reference>
  <results_reference>
    <citation>Tangen CM, Hussain M, Wilding G, et al.: Determinants of prostate specific antigen (PSA) normalization in prostate cancer (PCa) patients (pts) treated with androgen deprivation (AD) on Southwest Oncology Group (SWOG) study 9346 (INT-0162). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1591, 2003.</citation>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>October 23, 2012</lastchanged_date>
  <firstreceived_date>November 1, 1999</firstreceived_date>
  <responsible_party>
    <name_title>Laurence H. Baker</name_title>
    <organization>Southwest Oncology Group - Group Chair's Office</organization>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
